AR113487A1 - Análogos de incretina y sus usos - Google Patents

Análogos de incretina y sus usos

Info

Publication number
AR113487A1
AR113487A1 ARP180103573A ARP180103573A AR113487A1 AR 113487 A1 AR113487 A1 AR 113487A1 AR P180103573 A ARP180103573 A AR P180103573A AR P180103573 A ARP180103573 A AR P180103573A AR 113487 A1 AR113487 A1 AR 113487A1
Authority
AR
Argentina
Prior art keywords
incretine
analogues
activity
receptors
incretin analogs
Prior art date
Application number
ARP180103573A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR113487A1 publication Critical patent/AR113487A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Se proporcionan análogos de incretina que tienen actividad en cada uno de los receptores GIP, GLP-1 y glucagón. Los análogos de incretina tienen características estructurales que dan como resultado una actividad equilibrada y una duración de acción extendida en cada uno de estos receptores. También se proporcionan métodos para tratar enfermedades tales como diabetes mellitus, dislipidemia, hepatopatía grasa, síndrome metabólico, esteatohepatitis no alcohólica y obesidad.
ARP180103573A 2017-12-21 2018-12-06 Análogos de incretina y sus usos AR113487A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762608644P 2017-12-21 2017-12-21

Publications (1)

Publication Number Publication Date
AR113487A1 true AR113487A1 (es) 2020-05-06

Family

ID=65003515

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103573A AR113487A1 (es) 2017-12-21 2018-12-06 Análogos de incretina y sus usos

Country Status (24)

Country Link
US (1) US11834486B2 (es)
EP (1) EP3727425A1 (es)
JP (2) JP6987993B2 (es)
KR (1) KR102440323B1 (es)
CN (1) CN111511387A (es)
AR (1) AR113487A1 (es)
AU (1) AU2018388895B2 (es)
BR (1) BR112020010410A2 (es)
CA (1) CA3084004C (es)
CL (1) CL2020001636A1 (es)
CO (1) CO2020006253A2 (es)
CR (1) CR20200256A (es)
DO (1) DOP2020000124A (es)
EA (1) EA202091284A1 (es)
EC (1) ECSP20032306A (es)
IL (1) IL275469A (es)
JO (1) JOP20200136A1 (es)
MA (1) MA51287A (es)
MX (1) MX2020006547A (es)
PH (1) PH12020551024A1 (es)
SG (1) SG11202004359YA (es)
TW (2) TWI767095B (es)
UA (1) UA127589C2 (es)
WO (1) WO2019125929A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI744579B (zh) * 2017-12-21 2021-11-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
EP3827015A1 (en) * 2018-07-23 2021-06-02 Eli Lilly and Company Gip/glp1 co-agonist compounds
TWI764209B (zh) * 2019-08-01 2022-05-11 美商美國禮來大藥廠 Gipr促效劑化合物
JP2022545200A (ja) 2019-08-19 2022-10-26 イーライ リリー アンド カンパニー インクレチン類似体を作製する方法
AR120714A1 (es) * 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
CN115298207A (zh) * 2020-01-23 2022-11-04 伊莱利利公司 Gip/glp1共激动剂化合物
EP4197560A1 (en) * 2020-08-14 2023-06-21 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising a triple-activator persistent conjugate as active ingredient
US20230391845A1 (en) 2020-10-30 2023-12-07 Novo Nordisk A/S Glp-1, gip and glucagon receptor triple agonists
AR125086A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Composiciones que contienen análogos de incretina y usos de estas
AU2022280225A1 (en) 2021-05-26 2024-01-04 The United Bio-Technology (Hengqin) Co., Ltd. Multi-agonist and use thereof
CN115572326A (zh) * 2021-06-21 2023-01-06 广东东阳光药业有限公司 Glp-1、gcg和gip受体的三重激动剂
WO2022271767A1 (en) 2021-06-23 2022-12-29 Eli Lilly And Company An incretin analog for use in glycemic control and weight management
WO2023088140A1 (zh) * 2021-11-19 2023-05-25 南京明德新药研发有限公司 订合肽及其应用
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN117417411A (zh) * 2022-09-28 2024-01-19 广东东阳光药业股份有限公司 Glp-1/gcg/gip三受体激动剂及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021146B1 (ru) 2009-03-27 2015-04-30 Глаксо Груп Лимитед Продукты слияния и конъюгаты лекарственных средств
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
TR201902516T4 (tr) * 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
KR102310389B1 (ko) * 2013-11-06 2021-10-13 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 효능제 화합물 및 방법
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TWI700291B (zh) * 2015-06-22 2020-08-01 美國禮來大藥廠 升糖素及glp-1共激動劑化合物
TWI807580B (zh) 2015-12-31 2023-07-01 南韓商韓美藥品股份有限公司 三重升糖素/glp-1/gip 受體促效劑
EP3217027A1 (de) 2016-03-08 2017-09-13 HILTI Aktiengesellschaft Breites einlageelement zum einfassen einer ankerstange
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途

Also Published As

Publication number Publication date
CA3084004A1 (en) 2019-06-27
AU2018388895A1 (en) 2020-06-04
CL2020001636A1 (es) 2020-10-16
CO2020006253A2 (es) 2020-05-29
ECSP20032306A (es) 2020-07-31
WO2019125929A1 (en) 2019-06-27
CA3084004C (en) 2023-06-20
SG11202004359YA (en) 2020-06-29
TWI767095B (zh) 2022-06-11
EA202091284A1 (ru) 2020-09-08
TW201938187A (zh) 2019-10-01
MX2020006547A (es) 2020-12-09
JP6987993B2 (ja) 2022-01-05
US11834486B2 (en) 2023-12-05
CR20200256A (es) 2020-07-12
CN111511387A (zh) 2020-08-07
TW202233227A (zh) 2022-09-01
JOP20200136A1 (ar) 2022-10-30
PH12020551024A1 (en) 2021-05-31
BR112020010410A2 (pt) 2020-11-24
AU2018388895B2 (en) 2020-12-24
KR20200088418A (ko) 2020-07-22
US20210221865A1 (en) 2021-07-22
TWI810937B (zh) 2023-08-01
DOP2020000124A (es) 2020-08-31
KR102440323B1 (ko) 2022-09-05
JP2022043082A (ja) 2022-03-15
JP2021506825A (ja) 2021-02-22
MA51287A (fr) 2021-03-31
IL275469A (en) 2020-08-31
UA127589C2 (uk) 2023-10-25
EP3727425A1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
ECSP20032650A (es) Análogos de incretina y sus usos
ECSP20032306A (es) Análogos de incretina y sus usos
CO2017001573A2 (es) Receptor quimérico de antígeno anti-cd123
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
ZA201903822B (en) Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
CO2017000510A2 (es) Constructos de car
DOP2017000102A (es) Coagonistas de los receptores de glucagón y de glp-1
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
TR201902516T4 (tr) Glukagon-glp-1-gıp üçlü agonist bileşikleri.
DOP2022000122A (es) Analogos de incretina y sus usos
AR101592A1 (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cd123
AR112904A1 (es) Proteínas de unión a antígenos anti-gitr y métodos para el uso de las mismas
UA92304U (ru) Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства противодиабетического действия для терапии инсулиннезависимого сахарного диабета